Madrigal poised to enter European MASH market after CHMP endorsement
Madrigal Pharmaceuticals has moved one step closer to marketing the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) in Europe after …
Post
-
-
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI) …
-
Podcast: The benefits of blockchain in healthcare
One of the key advantages of blockchain is that it removes the need for patients to provide the same information …
-
Novartis’ ribociclib approved in Canada for early breast cancer
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the …
-
FDA cell and gene therapy director exit increases ‘volatility’ for sector
The departure of the US Food and Drug Administration’s (FDA) cell and gene therapy director and deputy director fuels ongoing …
-
NSW government invests $13.39m in life-changing therapies
The government of New South Wales (NSW), Australia, has announced an investment of A$20.7m ($13.39m) in access to life-changing therapies …
-
DoH – Abu Dhabi and Sanofi link for vaccine development
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine …
-
CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value …
-
UK and US governments pursue contrasting vaccine strategies
While the outlook for vaccines in the US looks bleak under the current administration, the UK Government is pressing ahead …
-
Actio gains $66m to advance small molecule therapeutics pipeline
US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline …
-
BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals
BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory …
-
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs
In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for …
-
Draig secures $140m for neuropsychiatric disorder therapies
Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies …
-
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) …
-
NHS England chair suggests England can learn from European health schemes
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At …
